4
Changes in Ownership
Keros Therapeutics, Inc. Filed Acc 0001209191-23-036261
Chief Financial Officer sold 40,000 shares at an average $46.61 ($1,864,239)
- Chief Financial Officer acquired 40,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Regnante Keith Chief Financial Officer | 2023-06-08 | Option exercise 10b5-1 | +20,000 | $16.00 | $320,000 | 20,000 | D |
| Regnante Keith Chief Financial Officer | 2023-06-08 | Sale 10b5-1 | −17,301 | $47.66 | $824,566 | 2,699 | D |
| Regnante Keith Chief Financial Officer | 2023-06-08 | Sale 10b5-1 | −2,699 | $48.65 | $131,306 | 0 | D |
| Regnante Keith Chief Financial Officer | 2023-06-09 | Option exercise 10b5-1 | +20,000 | $16.00 | $320,000 | 20,000 | D |
| Regnante Keith Chief Financial Officer | 2023-06-09 | Sale 10b5-1 | −15,993 | $45.03 | $720,165 | 4,007 | D |
| Regnante Keith Chief Financial Officer | 2023-06-09 | Sale 10b5-1 | −1,428 | $46.46 | $66,345 | 2,579 | D |
| Regnante Keith Chief Financial Officer | 2023-06-09 | Sale 10b5-1 | −2,579 | $47.25 | $121,858 | 0 | D |
| Derivatives | |||||||
| Regnante Keith Chief Financial Officer | 2023-06-08 | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −20,000 | 113,622 | D | ||
| Regnante Keith Chief Financial Officer | 2023-06-09 | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −20,000 | 93,622 | D | ||
| Open-market sales · 40,000 sh · avg $46.61 · $1,864,239 | |||||||
Loading xslF345X04/doc4.xml…